Clinical Trial Update: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating monoclonal antibody 3F8 in combination with sargramostim for neuroblastoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 3F8 monoclonal antibody (anti-GD2 monoclonal antibody)
• sargramostim (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2022-05-16